Rhodamine-123: Therapy for hormone refractory prostate cancer, a phase I clinical trial

Journal of Chemotherapy

Volumn 17, Issue 4, 2005, Pages 435-440

  Jones, Lawrence W ^a   Narayan, K S ^a   Shapiro, C E ^a   Sweatman, T W ^b  

^a HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Anti mitochondrial; Chemotherapy; Clinical trial; Prostate cancer; Rhodamine 123

Indexed keywords

PROSTATE ANTIGEN; RHODAMINE 123;

ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG RETENTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; HUMAN TISSUE; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MALE; PHASE 1 CLINICAL TRIAL; PROSTATE CANCER; RASH; SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

EID: 24644499548     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.4.435     Document Type: Article

References (15)

1. Stamey TA, McNeal JE. Adenocarcinoma of the prostate. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED, eds. Campbell's Urology. Philadelphia: W.B. Sanders Co. 1992: 1159-1221.
2. Modica-Napolitano JS, Aprille JR. Basis for selective cytotoxicity of rhodamine-123. Cancer Res 1987; 47 (16): 4361-4365.
3. Johnson LV, Walsh ML, Chen LB, Localization of mitochondria in living cells with rhodamine 123. Proc Natl Acad Sci USA 1980; 77 (2): 990-994.
4. Summerhayes IC, Lampidis TJ, Bernai SD et al. Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Proc Natl Acad Sci USA 1982; 79 (17): 5292-5296.
5. Lampidis TJ, Bernal SD, Summerhayes IC, Chen LB. Selective toxicity of rhodamine-123 in carcinoma cells in vitro. Cancer Res 1983; 43 (2): 716-720.
6. Arcadi JA. Rhodamine-123 as effective agent in rat prostate tumor R3327-H. Urology 1986; 28 (6): 501-503.
7. Arcadi JA, Narayan KS, Techy G, Ng CP, Saroufeem RMG, Jones LW. Studies of rhodamine-123: effect on rat prostate cancer and human prostate cancer cells in vitro. J Surg Oncol 1995; 59 (12): 86-93.
8. Green S, Weiss GR. Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10 (4): 239-253.
9. Sweatman TW, Larussa RI, Seshadri R, Israel M. An analytical system for the detection and quantitation of rhodamine-123 in biological samples. J Liq Chromotogr 1987; 10 (1): 1417-1429.
10. Sweatman TW, Seshadri R, Israel M. Metabolism and elimination of rhodamine 123 in the rat. Cancer Chemother Pharmacol 1990; 27 (3): 205.
11. Kelloff GJ, Coffey DS, Chabner BA et al. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res 2004; 10 (11): 3927-3933.
12. Britten CD, Rowinsky EK, Baker SD et al. A phase I pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077. Clin Cancer Res 2000; 6 (1): 42-49.
13. Chi KN, Gleave ME, Klasa R et al. A phase I dose-finding study of combined treatment with an antisense Bel-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res. 2001; 7 (12): 3920-3927.
14. Oh WK, Halabi S, Kelly WK et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma. Cancer 2003; 98 (12): 2592-2598.
15. Modica-Napolitano JS, Nalbandian R, Kidd ME, Nalbandian A, Nguyen CC. The selective in vitro cytotoxicity of carcinoma cells by AZT is enhanced by concurrent treatment with delocalized lipophilic cations. Cancer Lett 2003; 198 (1): 59-68.